The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
暂无分享,去创建一个
I. Pavord | C. Brightling | R. Chaudhuri | J. Busby | L. Heaney | P. J. McDowell | S. Diver | Freda Yang | C. Borg | V. Brown | R. Shrimanker | C. Cox | F. Yang
[1] P. Nair,et al. Asthma exacerbations on benralizumab are largely non‐eosinophilic , 2020, Allergy.
[2] I. Pavord,et al. Response to mepolizumab treatment is sustained across 4-weekly dosing periods , 2020, ERJ Open Research.
[3] Xin-chun Yang,et al. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019 , 2020, Allergy.
[4] Z. Wang,et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study , 2020, EClinicalMedicine.
[5] M. Rothenberg,et al. Eosinophil responses during COVID-19 infections and coronavirus vaccination , 2020, Journal of Allergy and Clinical Immunology.
[6] G. Canonica,et al. The evolving algorithm of biological selection in severe asthma , 2020, Allergy.
[7] L. Heaney,et al. Different endotypes and phenotypes drive the heterogeneity in severe asthma , 2020, Allergy.
[8] S. Yancey,et al. Characterisation of Exacerbations of Severe Eosinophilic Asthma on Mepolizumab Compared to Placebo , 2019, B21. SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES.
[9] I. Pavord,et al. Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma , 2019, American journal of respiratory and critical care medicine.
[10] I. Pavord,et al. Exacerbations of severe asthma in patients treated with mepolizumab , 2018, European Respiratory Journal.
[11] I. Pavord,et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles , 2018, Journal of Allergy and Clinical Immunology.
[12] James J. Lee,et al. Sputum autoantibodies in patients with severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.
[13] C. Jenkins,et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.
[14] F. Albers,et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.
[15] H. Ortega,et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone‐dependent severe asthma , 2016, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[16] K. Ravin,et al. The Eosinophil in Infection , 2016, Clinical Reviews in Allergy & Immunology.
[17] Mike Thomas,et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.
[18] I. Pavord,et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function , 2015, International journal of chronic obstructive pulmonary disease.
[19] D. Khatry,et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. , 2014, The journal of allergy and clinical immunology. In practice.
[20] Ian D Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.
[21] James J. Lee,et al. The consequences of not having eosinophils , 2013, Allergy.
[22] E. R. Sutherland,et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.
[23] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[24] S. Stanojevic,et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.
[25] Christopher E Brightling,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.
[26] L. Spencer,et al. Eosinophils in innate immunity: an evolving story , 2010, Cell and Tissue Research.
[27] Barmak Modrek,et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.
[28] Ana Sousa,et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.
[29] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[30] G H Guyatt,et al. Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.
[31] G. Guyatt,et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. , 1999, The European respiratory journal.
[32] I. Pavord,et al. Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.
[33] P. Jones,et al. The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.